Janux Therapeutics (NASDAQ:JANX) Given New $150.00 Price Target at Cantor Fitzgerald

Janux Therapeutics (NASDAQ:JANX) had its price objective lowered by Cantor Fitzgerald from $200.00 to $150.00 in a research note issued to investors on Tuesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Several other equities research analysts also recently issued reports on the stock. Barclays lifted their price target on shares of Janux Therapeutics from $47.00 to $48.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Piper Sandler initiated coverage on Janux Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $42.00 target price for the company. Truist Financial initiated coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 price target on the stock. Guggenheim initiated coverage on Janux Therapeutics in a report on Wednesday, September 3rd. They issued a “buy” rating and a $72.00 price target for the company. Finally, Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $62.67.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $15.86 on Tuesday. The firm has a market capitalization of $953.98 million, a PE ratio of -9.44 and a beta of 2.82. Janux Therapeutics has a one year low of $15.77 and a one year high of $71.71. The stock’s 50 day moving average price is $27.15 and its 200 day moving average price is $25.37.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $3.07 million. On average, analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $30.00, for a total transaction of $99,990.00. Following the sale, the insider owned 84,974 shares in the company, valued at $2,549,220. This represents a 3.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 29.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors have recently made changes to their positions in JANX. RA Capital Management L.P. lifted its stake in Janux Therapeutics by 7.9% during the first quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company’s stock worth $302,122,000 after purchasing an additional 824,041 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Janux Therapeutics by 19.4% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company’s stock worth $98,673,000 after purchasing an additional 592,824 shares during the period. Vanguard Group Inc. lifted its position in shares of Janux Therapeutics by 10.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after buying an additional 227,676 shares during the last quarter. Orbimed Advisors LLC boosted its holdings in shares of Janux Therapeutics by 45.9% in the 3rd quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock valued at $43,163,000 after buying an additional 555,800 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Janux Therapeutics by 25.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,392,826 shares of the company’s stock valued at $37,607,000 after buying an additional 282,848 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.